This concurrent resolution designates February 28, 2025 as Rare Disease Day in California and formally recognizes the importance of raising awareness, improving early and accurate diagnosis, and supporting efforts to develop treatments, diagnostics, and cures for rare diseases. It contains findings about federal and state activity on rare diseases and directs the Assembly’s Chief Clerk to transmit copies of the resolution to the author for distribution.
The measure is ceremonial and contains no appropriations; its practical effect is to signal a legislative priority and to elevate visibility for patients, advocacy groups, researchers, and the newly formed state advisory council that advises the Legislature on rare‑disease issues.
At a Glance
What It Does
The resolution formally designates February 28, 2025 as Rare Disease Day for California and records legislative findings about rare‑disease prevalence, federal programs, and California’s life‑sciences role. It does not create regulatory mandates, funding, or new legal rights; it requests distribution of the text to the author for further outreach.
Who It Affects
The resolution primarily affects patients and families living with rare conditions, advocacy organizations, the California Jacqueline Marie Zbur Rare Disease Advisory Council, researchers and life‑sciences companies with rare‑disease programs, and state legislative staff involved in related policy work. It does not impose obligations on private parties or state agencies.
Why It Matters
As a visibility tool, the resolution consolidates several strands — federal FDA programs, the Orphan Drug Act anniversary, and California’s research leadership — into a single legislative statement. For stakeholders, that signal can catalyze attention from policymakers, funders, and institutions even though the resolution itself carries no funding or regulatory force.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The text collects a set of factual findings about rare diseases and then uses a concurrent resolution to single out the last day of February 2025 as Rare Disease Day in California. The findings summarize federal and state activity — the Orphan Drug Act milestone, FDA programs intended to accelerate rare‑disease drug development, and California’s research strengths — and list examples of rare conditions to illustrate the scope of the problem.
Because the measure is a concurrent resolution, it operates as a formal expression of the Legislature’s view rather than as law imposing duties or funding. The resolution explicitly recognizes challenges commonly faced by rare‑disease patients: diagnostic delays, difficulties locating providers with relevant expertise, and high costs of care.
It links those observations to existing federal efforts (FDA programs) and to a California advisory council created in 2024 that is charged with advising the Legislature on access and care issues.Practically, the resolution does three things: it aggregates and publishes legislative findings that stakeholders can cite, it designates a specific date for heightened public attention, and it directs clerical transmission of the resolution for distribution. Those actions can help advocacy organizations and researchers coordinate events, encourage agencies and funders to take notice, and set the stage for future, concrete legislative or budgetary proposals.
The text does not promise funding or new regulatory programs and leaves open how state agencies or private actors will respond to the signal.
The Five Things You Need to Know
The resolution designates February 28, 2025 as Rare Disease Day in California.
It cites the federal definition used in the United States: a rare disease affects fewer than 200,000 people.
The text references the 42nd anniversary of the federal Orphan Drug Act to frame historical progress on rare‑disease therapies.
The resolution names two federal initiatives — the FDA’s Accelerating Rare disease Cures Program and the rare disease endpoint advancement pilot program created in the Consolidated Appropriations Act of 2023 — as relevant federal activity.
The measure instructs the Chief Clerk of the Assembly to transmit copies of the resolution to the author for distribution, a typical clerical step for ceremonial measures.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Findings on prevalence, burden, and existing programs
The resolution’s preamble compiles factual findings: it adopts the U.S. rarity threshold (fewer than 200,000 people), cites the large number of distinct rare conditions, notes the proportion of pediatric cases, and lists example diseases. It also records federal milestones and programs (the Orphan Drug Act, FDA initiatives) and highlights California’s research contributions. These findings create a single, legislative statement of the problem—useful for advocates and agencies that need a concise compilation of state legislative recognition.
Designates Rare Disease Day and states policy priorities
The central operative clause formally designates February 28, 2025 as Rare Disease Day and articulates priorities: improving awareness, encouraging accurate and early diagnosis, and supporting national and global efforts to develop treatments and diagnostics. Because this is a concurrent resolution, the clause has symbolic force rather than regulatory effect — it frames intended priorities without creating enforceable duties or entitlements.
Connects state recognition to federal programs and a state advisory council
The text explicitly references federal FDA programs that aim to accelerate rare‑disease development and a California advisory council established in 2024. That linkage signals to federal agencies, state advisory bodies, and researchers that the Legislature views those programs as relevant levers. It also narrows the resolution’s focus to research facilitation, diagnosis, and awareness rather than insurance coverage or reimbursement reforms.
Directs distribution of the resolution
The resolution concludes by directing the Chief Clerk of the Assembly to transmit copies to the author for appropriate distribution. This is a routine administrative step that enables the author and stakeholder groups to disseminate the legislative text to agencies, organizations, and the public.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients and families affected by rare diseases — the resolution raises public and legislative attention, which can help advocacy groups secure meetings, media coverage, and visibility for unmet clinical needs.
- Rare‑disease advocacy organizations — they gain a legislative platform to coordinate events, educative campaigns, and to reference state recognition when approaching funders or agencies.
- California life‑sciences and academic research institutions — the resolution highlights the state’s role in originations of rare‑disease treatments, potentially strengthening their case for partnership and philanthropic or public support.
- Jacqueline Marie Zbur Rare Disease Advisory Council — legislative recognition supports the council’s visibility and may increase uptake of its recommendations by the Legislature and state agencies.
- Clinics and centers of excellence specializing in rare conditions — higher public awareness can lead to more referrals and strengthened case for specialized services.
Who Bears the Cost
- Legislative staff and the Chief Clerk’s office — minor administrative time to process and distribute the resolution and to respond to stakeholder inquiries.
- State agencies and public health units if they voluntarily choose to run awareness campaigns — while the resolution does not allocate funds, agencies might face discretionary costs if they act on the signal.
- Healthcare providers and diagnostic centers — increased awareness can raise demand for specialist consultations and testing, affecting scheduling and resource allocation in the short term.
- Advocacy groups seeking follow‑up — recognition raises expectations for concrete policy outcomes, potentially increasing advocacy workload to translate visibility into funding or statutory changes.
Key Issues
The Core Tension
The central tension is between symbolic recognition and the need for concrete action: the Legislature signals urgency for rare‑disease awareness and research, yet the resolution does not allocate resources or change law, leaving patients and providers to press for follow‑up measures that may require budgetary commitments and regulatory work.
The resolution is entirely symbolic: it records findings, designates a date, and requests clerical distribution. It contains no appropriation and imposes no regulatory obligations.
That symbolic nature is both its strength and its limitation — the measure can focus attention quickly, but it does not create new programs, funding streams, or legal entitlements that patients and families often need.
Because the text aggregates many facts (federal programs, historical milestones, a long list of example conditions), it risks generating expectations that the Legislature will follow with concrete policy or budgetary proposals. Implementation questions are unresolved: which state agencies, if any, should lead outreach; whether the advisory council’s recommendations will translate into funded programs; and how the state will coordinate with federal FDA initiatives.
Finally, the resolution uses the standard U.S. rarity threshold (<200,000) and cites a broad array of conditions; those choices frame policy conversations but do not resolve difficult tradeoffs about prioritization, access to care, or financing high‑cost therapies.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.